November 2022
Regulation of Human Cells, Tissues,
and Cellular and Tissue-Based
Products (HCT/Ps)
Small Entity Compliance Guide
CORD BLOOD CLINICAL TRIAL RECEIVES FDA AUTHORIZATION
Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products:
Minimal Manipulation and Homologous Use
FDA Issues Extension period to May 31, 2021 for minimal manipulation products.
Maximum Signaling for Maximum Regeneration
RichSource Announces Non-Invasive Breakthrough Product RICHGEN
